Literature DB >> 12600942

Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.

Edward J Gunther1, Susan E Moody, George K Belka, Kristina T Hahn, Nathalie Innocent, Katherine D Dugan, Robert D Cardiff, Lewis A Chodosh.   

Abstract

Aberrant activation of Wnt signaling is oncogenic and has been implicated in a variety of human cancers. We have developed a doxycycline-inducible Wnt1 transgenic mouse model to determine the dependence of established mammary adenocarcinomas on continued Wnt signaling. Using this model we show that targeted down-regulation of the Wnt pathway results in the rapid disappearance of essentially all Wnt-initiated invasive primary tumors as well as pulmonary metastases. Tumor regression does not require p53 and occurs even in highly aneuploid tumors. However, despite the dependence of primary mammary tumors and metastases on continued Wnt signaling and the dispensability of p53 for tumor regression, we find that a substantial fraction of tumors progress to a Wnt-independent state and that p53 suppresses this process. Specifically, loss of one p53 allele dramatically facilitates the progression of mammary tumors to a Wnt1-independent state both by impairing the regression of primary tumors following doxycycline withdrawal and by promoting the recurrence of fully regressed tumors in the absence of doxycycline. Thus, although p53 itself is dispensable for tumor regression, it nevertheless plays a critical role in the suppression of tumor recurrence. Our findings demonstrate that although even advanced stages of epithelial malignancy remain dependent upon continued Wnt signaling for maintenance and growth, loss of p53 facilitates tumor escape and the acquisition of oncogene independence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12600942      PMCID: PMC195997          DOI: 10.1101/gad.1051603

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  39 in total

1.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 2.  Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.

Authors:  Mercedes E Gorre; Charles L Sawyers
Journal:  Curr Opin Hematol       Date:  2002-07       Impact factor: 3.284

3.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

4.  Transgenic oncogene mice. Tumor phenotype predicts genotype.

Authors:  R D Cardiff; E Sinn; W Muller; P Leder
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

5.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.

Authors:  A S Tsukamoto; R Grosschedl; R C Guzman; T Parslow; H E Varmus
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

6.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

7.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

8.  ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias.

Authors:  A R Moser; E M Mattes; W F Dove; M J Lindstrom; J D Haag; M N Gould
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

9.  Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei.

Authors:  L L Vindelov
Journal:  Virchows Arch B Cell Pathol       Date:  1977-08-10

10.  Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland.

Authors:  A Imbert; R Eelkema; S Jordan; H Feiner; P Cowin
Journal:  J Cell Biol       Date:  2001-04-30       Impact factor: 10.539

View more
  92 in total

1.  p53 and microRNA-34 are suppressors of canonical Wnt signaling.

Authors:  Nam Hee Kim; Hyun Sil Kim; Nam-Gyun Kim; Inhan Lee; Hyung-Seok Choi; Xiao-Yan Li; Shi Eun Kang; So Young Cha; Joo Kyung Ryu; Jung Min Na; Changbum Park; Kunhong Kim; Sanghyuk Lee; Barry M Gumbiner; Jong In Yook; Stephen J Weiss
Journal:  Sci Signal       Date:  2011-11-01       Impact factor: 8.192

Review 2.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

3.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

Review 4.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

5.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector.

Authors:  Young Chul Kim; Rod J Clark; Erik A Ranheim; Caroline M Alexander
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 7.  Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.

Authors:  Brandon Kocher; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2013-04-12       Impact factor: 39.397

8.  Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.

Authors:  Nathaniel W Mabe; Douglas B Fox; Ryan Lupo; Amy E Decker; Stephanie N Phelps; J Will Thompson; James V Alvarez
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

9.  Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction.

Authors:  Martin Jechlinger; Katrina Podsypanina; Harold Varmus
Journal:  Genes Dev       Date:  2009-07-15       Impact factor: 11.361

Review 10.  Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Breast Cancer Res       Date:  2008-09-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.